Genmab A/S (NASDAQ: GMAB) has reported positive topline results from its global Phase 3 RAINFOL-02 trial showing that investigational rinatabart sesutecan, known as Rina-S, significantly improved both progression-free survival and overall survival compared with investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer. Announced on October 23, 2026, the findings showed a 71% reduction in the hazard of disease progression or death and a 57% reduction in the hazard of death in the overall intention-to-treat population, strengthening the clinical evidence supporting the company’s folate receptor alpha-targeted antibody-drug conjugate.
The results represent the first successful Phase 3 readout from Genmab’s Rina-S development programme and mark a substantial advance beyond the response-rate findings previously reported in early-stage trials. Both the prespecified primary endpoint of progression-free survival and the key secondary endpoint of overall survival were met in the overall study population and a separately defined primary analysis population.
The development is particularly relevant because platinum-resistant ovarian cancer remains difficult to treat after progression on platinum-based chemotherapy, with outcomes often worsening following successive systemic regimens. However, the October disclosure contains topline data rather than a complete clinical dataset, and Genmab has not yet reported median progression-free survival, median overall survival or detailed Phase 3 adverse-event frequencies.
The immediate importance is therefore twofold. The findings provide randomised evidence that Rina-S can outperform selected single-agent chemotherapy options on two clinically consequential endpoints, while creating a potential path toward regulatory discussions. Its eventual clinical role will depend on the full safety and efficacy findings, folate receptor alpha subgroup analyses and how the investigational treatment compares with an evolving standard of care.
What do the Phase 3 RAINFOL-02 results show about Rina-S and progression-free survival?
RAINFOL-02 is a global, randomised, open-label Phase 3 trial evaluating rinatabart sesutecan against investigator’s choice chemotherapy in patients with platinum-resistant ovarian cancer. The study’s intention-to-treat population included 584 randomised participants, with treatment assigned equally between Rina-S and chemotherapy. The investigational treatment was administered at 120 milligrams per square metre on the first day of each three-week cycle.
Patients assigned to the comparator group received one of four established chemotherapy treatments: paclitaxel, topotecan, pegylated liposomal doxorubicin or gemcitabine. The study’s primary endpoint was progression-free survival assessed by investigators, while overall survival and objective response rate were among the key secondary efficacy measures. The design allows the investigational therapy to be compared against several conventional chemotherapy options used in this treatment setting.
In the intention-to-treat population, Rina-S demonstrated a progression-free survival hazard ratio of 0.29 compared with chemotherapy. The 95% confidence interval ranged from 0.23 to 0.37, and the p-value was below 0.0001. This corresponds to a 71% lower hazard of progression or death over the observation period, providing statistically strong evidence favouring Rina-S on the primary endpoint.
The same benefit was observed in the trial’s primary analysis population, which included 492 participants meeting additional criteria related to folate receptor alpha expression and previous treatment. In this population, the progression-free survival hazard ratio was 0.33, with a 95% confidence interval of 0.26 to 0.42 and a p-value below 0.0001. The result represents a 67% lower hazard of progression or death compared with the assigned chemotherapy regimens.
The consistency between these two populations supports the robustness of the topline efficacy finding. However, the results should not be interpreted as demonstrating the same treatment effect in every folate receptor alpha subgroup because detailed subgroup estimates have not yet been disclosed. It is also important to distinguish a hazard reduction from an absolute reduction in the percentage of patients experiencing an event.
Genmab has not provided the median progression-free survival values for either treatment arm. Without those figures, clinicians cannot yet assess the difference in median time without progression or evaluate the shape of the survival curves. These details will be important in determining the practical magnitude and durability of benefit associated with Rina-S.
Why is the overall survival result particularly important for platinum-resistant ovarian cancer?
Overall survival is a clinically consequential endpoint because it directly measures the time patients remain alive following randomisation. Unlike progression-free survival, which can be influenced by imaging schedules and disease assessment methods, overall survival provides a direct measure of mortality outcomes. Demonstrating statistically significant improvement on both endpoints strengthens the evidence supporting a new oncology treatment.
Genmab reported an overall survival hazard ratio of 0.43 in the intention-to-treat population, with a 95% confidence interval of 0.31 to 0.59 and a p-value below 0.0001. This represents a 57% lower hazard of death during the trial’s observation period among patients assigned to Rina-S compared with those receiving investigator’s choice chemotherapy. The result supports a substantial relative treatment effect, although it does not mean that 57% fewer patients necessarily died over a fixed period.
In the primary analysis population, the overall survival hazard ratio was 0.44, with a 95% confidence interval of 0.31 to 0.63 and a p-value below 0.0001. The consistency of the survival findings across the two defined analysis populations adds credibility to the efficacy signal. However, the company has not yet provided median overall survival, survival probabilities at specified time points or detailed information on follow-up maturity.
Those additional measurements will be essential to interpreting clinical meaningfulness beyond the relative hazard reduction. For example, the difference in median survival could help clinicians and patients understand the treatment effect in more familiar time-based terms. The proportion of patients remaining alive at one or two years could also provide information about whether the survival curves remain separated over extended follow-up.
The trial’s open-label design is another consideration. Overall survival is generally less susceptible to assessment bias than investigator-assessed progression-free survival, but subsequent therapies, treatment discontinuations and patterns of follow-up can still influence interpretation. Detailed information on post-progression treatment and crossover arrangements, if applicable, will therefore be relevant.
Genmab has described the overall survival result as clinically meaningful, an assessment supported by the magnitude and statistical strength of the disclosed hazard ratios. The complete dataset will establish how that relative benefit translates into survival duration, treatment burden and outcomes across different patient populations.
How does Rina-S target folate receptor alpha, and why is its payload different from existing ovarian cancer ADCs?
Rinatabart sesutecan is an antibody-drug conjugate designed to bind folate receptor alpha, a cell-surface protein expressed in varying amounts across several solid tumors, including ovarian cancer. The therapy combines a human monoclonal antibody targeting the receptor with a hydrophilic, protease-cleavable linker and an exatecan cytotoxic payload. Exatecan inhibits topoisomerase I, an enzyme involved in the processes required for DNA replication and repair.
Antibody-drug conjugates are designed to deliver cytotoxic medicines to cells expressing selected molecular targets while potentially limiting exposure to some normal tissues. Following target binding and internalisation, the linker and payload are intended to enable delivery of the cytotoxic component within the tumor environment. The therapeutic effect depends on several factors, including target expression, cellular uptake, linker stability, payload activity and the susceptibility of cancer cells to the mechanism.
The use of exatecan differentiates Rina-S from AbbVie’s ELAHERE (mirvetuximab soravtansine), another folate receptor alpha-targeted antibody-drug conjugate. ELAHERE delivers a maytansinoid payload that acts on microtubules, whereas Rina-S uses topoisomerase I inhibition. These different cytotoxic mechanisms may influence activity and resistance, although their clinical significance cannot be established without appropriate comparative evidence.
Folate receptor alpha expression also varies among patients and tumors. Some ovarian cancers express high levels of the receptor, while others show lower or heterogeneous expression. A treatment capable of producing meaningful activity across a broad range of expression levels could potentially address patients outside the population eligible for currently approved receptor-selected therapies.
However, the ability of an antibody-drug conjugate to act in tumors with low target expression depends on its specific pharmacological properties and the biological characteristics of the tumor. It should not be assumed that low or absent receptor expression is irrelevant simply because efficacy was demonstrated in a trial enrolling patients without a universal expression threshold. Detailed biomarker analyses remain necessary to determine whether expression levels influence the magnitude of treatment benefit.
Can Rina-S benefit patients regardless of folate receptor alpha expression?
One of the distinctive features of RAINFOL-02 is that the intention-to-treat population included patients regardless of folate receptor alpha expression. This differs from treatment strategies that require high receptor expression as a condition of eligibility. The broader enrolment approach creates an opportunity to investigate the potential activity of Rina-S across a wider ovarian cancer population.
The trial also included a primary analysis population of 492 patients defined partly by their eligibility for and prior exposure to mirvetuximab. This population included patients with folate receptor alpha expression below the high-expression threshold, together with patients meeting the high-expression criterion who had previously received mirvetuximab when that treatment was available in the relevant region. The definition reflects the changing treatment landscape, particularly where an approved folate receptor alpha-targeted therapy is already used.
The high-expression threshold involved at least 75% of viable tumor cells demonstrating staining intensity of 2+ or greater under the applicable scoring approach. This criterion is closely associated with the patient-selection framework used for mirvetuximab. Its inclusion in the RAINFOL-02 analysis structure helps account for the clinical implications of prior access to that treatment.
The significant efficacy results in both analysis populations suggest that Rina-S’s overall benefit was not dependent on excluding every patient with lower receptor expression. However, the results do not establish equal efficacy in patients with high, low or absent expression, because the company has not reported separate hazard ratios and confidence intervals for those subgroups. The statement that the trial enrolled patients regardless of expression must therefore be distinguished from a definitive conclusion that expression does not affect treatment benefit.
Further analyses will be particularly important for identifying whether a minimum expression threshold is needed for optimal treatment selection. If the benefit remains clinically meaningful in low-expression or non-expressing tumors, Genmab may have a rationale for seeking a broader indication than therapies requiring a positive biomarker test. That possibility remains dependent on the full efficacy dataset and regulatory review.
The analysis of patients previously treated with mirvetuximab will also attract attention. A treatment targeting the same receptor but delivering a different cytotoxic payload might retain activity after exposure to another antibody-drug conjugate, although resistance mechanisms can vary. The overall trial result does not independently establish efficacy specifically after mirvetuximab failure, and dedicated subgroup evidence will be needed to evaluate that question.
How do the Phase 3 findings build on Genmab’s earlier RAINFOL-01 clinical results?
The Phase 3 readout follows encouraging findings from the earlier RAINFOL-01 development programme. On October 3, 2026, Genmab reported results from Part C of the Phase 1/2 study involving 109 patients with platinum-resistant ovarian cancer treated with Rina-S at 120 milligrams per square metre every three weeks. The company reported a confirmed objective response rate of 45.9%, including five complete responses.
The median duration of response was 12.1 months, while median progression-free survival was 9.5 months in that cohort. Approximately 51% of responding patients remained in response at one year. These findings provided evidence of antitumor activity and response durability in a population that had received substantial previous treatment.
The Phase 1/2 cohort included patients with high-grade serous ovarian, primary peritoneal or fallopian tube cancer. More than half had received three or four prior lines of therapy, all had received bevacizumab and taxane treatment, and approximately one-third had previously received mirvetuximab. These characteristics made the findings relevant to a heavily pretreated population with limited treatment options.
The earlier study was not designed to provide the same comparative evidence as RAINFOL-02. Response rates observed in a single-arm cohort cannot establish superiority over chemotherapy or reliably quantify an overall survival benefit. The Phase 3 trial therefore represents an important advance because it uses randomisation and an active comparator to assess treatment effects.
The two studies also should not be treated as directly interchangeable datasets. Differences in eligibility criteria, prior therapy, baseline disease characteristics and outcome assessment can influence observed efficacy measures. The Phase 1/2 findings provide supportive background, while RAINFOL-02 supplies the more consequential comparative evidence.
Together, the results suggest that the early antitumor activity identified during dose development has translated into a statistically significant treatment advantage in a larger randomised population. The next step is to determine whether the detailed Phase 3 response, survival and safety findings are consistent with the broader clinical profile suggested by the early-stage programme.
What does the available safety evidence show about Rina-S treatment?
Genmab reported that the Phase 3 safety profile was consistent with previous clinical experience and that no new safety signals or unexpected safety concerns had been identified. This statement provides an initial indication that investigators did not observe a previously unrecognised safety pattern that substantially changed the company’s assessment. However, the October 23 announcement did not include detailed adverse-event rates for the randomised Phase 3 population.
The earlier RAINFOL-01 study provides some context for the types of adverse events associated with Rina-S. In the 109-patient Part C cohort, nausea was reported in 67.9% of participants, fatigue in 57.8%, vomiting in 36.7% and decreased appetite in 23.9%. These findings indicate that gastrointestinal symptoms and fatigue were common during treatment.
Hematological adverse events were also reported. Anemia and neutropenia each occurred in 57.8% of treated participants, while decreased platelet count and thrombocytopenia were each recorded in 34.9%. Serious adverse events were reported in approximately one-third of participants, and treatment discontinuation due to treatment-emergent adverse events occurred in 5.5%.
The Phase 1/2 report did not identify safety signals for ocular toxicity, peripheral neuropathy, interstitial lung disease or stomatitis within that cohort. These observations should not be interpreted as proof that such complications cannot occur in larger populations or during prolonged treatment. Differences in patient characteristics, cumulative exposure and adverse-event detection may become relevant as the clinical database expands.
The full RAINFOL-02 safety report will need to clarify the frequency of Grade 3 or higher adverse events, serious treatment-related events, dose reductions, interruptions, discontinuations and deaths. The relationship between adverse events and exposure duration will also matter when evaluating a therapy that produced a substantial progression-free survival benefit and may consequently be administered for longer periods.
The comparison with chemotherapy will be central to the benefit-risk assessment. A strong efficacy result may support the use of a treatment with meaningful adverse effects, but clinicians still need to understand whether toxicity can be managed without undermining treatment continuity or quality of life. Detailed comparative safety evidence will therefore be essential before determining how Rina-S might be used in routine practice.
How does the existing ovarian cancer treatment landscape affect Rina-S’s commercial opportunity?
The treatment environment for platinum-resistant ovarian cancer has expanded beyond conventional single-agent chemotherapy. AbbVie’s ELAHERE received full United States Food and Drug Administration approval in March 2024 for adults with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who had received one to three prior systemic treatment regimens. That approval established an antibody-drug conjugate treatment option for patients meeting the applicable biomarker criteria.
A further development occurred in March 2026 when the Food and Drug Administration approved Corcept Therapeutics’ LIFYORLI (relacorilant) in combination with nab-paclitaxel. The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens, including at least one bevacizumab-containing regimen. The decision introduced another treatment option supported by randomised progression-free and overall survival findings.
These approvals mean that Rina-S’s potential commercial positioning must be considered in a treatment landscape broader than the chemotherapy drugs used in its control arm. The RAINFOL-02 results establish superiority over the selected investigator’s choice chemotherapy regimens, but they do not demonstrate superiority over ELAHERE or the approved relacorilant combination. Direct cross-trial comparisons would be unreliable because of differences in patient selection, previous treatment, endpoints and study design.
A potential advantage for Genmab is the inclusion of patients across folate receptor alpha expression levels. If regulatory authorities determine that the full dataset supports broad eligibility, Rina-S could potentially address patients who are not candidates for receptor-selected treatment. However, the authorised population cannot be predicted solely from the intention-to-treat result, and a future label may include eligibility or prior-treatment restrictions.
Treatment sequencing will be another commercial consideration. Clinicians may need to decide whether Rina-S is most appropriate before or after other targeted therapies, how previous antibody-drug conjugate exposure affects benefit and which patients are likely to tolerate its cytotoxic payload. Evidence from RAINFOL-02 and subsequent studies will need to inform those decisions.
Commercial adoption will also depend on pricing, reimbursement, infusion capacity, toxicity monitoring and regional treatment availability. A favourable Phase 3 result can support regulatory development, but it does not establish an immediate revenue opportunity until the treatment receives the necessary authorisations and commercial arrangements are in place.
Why do the RAINFOL-02 findings matter for Genmab’s $1.8 billion ProfoundBio acquisition?
Genmab obtained rinatabart sesutecan through its acquisition of ProfoundBio, completed in May 2024 for approximately $1.8 billion in cash, subject to customary closing adjustments. The transaction gave Genmab worldwide rights to Rina-S, additional clinical-stage antibody-drug conjugate candidates and the acquired company’s technology platforms. It formed part of a strategy to expand Genmab’s wholly owned oncology pipeline beyond its established antibody development activities.
The RAINFOL-02 success provides an important clinical development milestone for an asset central to that transaction. Genmab acquired the programme before the current Phase 3 efficacy findings were available, meaning that the purchase involved substantial clinical and commercial uncertainty. Demonstrating statistically significant improvements in progression-free and overall survival reduces one major category of development uncertainty, although it does not establish the acquisition’s eventual financial return.
The company’s broader financial position provides context for the programme’s strategic importance. Genmab reported revenue of $2.05 billion for the first six months of 2026, representing 25% growth from the corresponding period of 2025. The increase was primarily supported by royalty income from partnered medicines and higher sales of its commercial products.
Genmab’s development strategy increasingly combines earnings generated from established antibody partnerships with investment in proprietary medicines and new therapeutic platforms. Rina-S is particularly relevant because it offers a potential wholly owned oncology product with multiple indications under investigation. Successful development could contribute to future revenue diversification, although commercial potential cannot yet be quantified reliably.
The company is evaluating Rina-S across several additional Phase 3 programmes, including recurrent or progressive endometrial cancer, platinum-sensitive ovarian cancer maintenance therapy and other ovarian cancer settings. Separate Phase 2 studies are investigating the medicine in non-small cell lung cancer and advanced gastrointestinal malignancies. These programmes extend the commercial opportunity but also carry independent clinical risks that cannot be resolved by the RAINFOL-02 findings.
The acquisition’s longer-term value will depend on regulatory approvals, the commercial performance of Rina-S and the progress of the broader antibody-drug conjugate portfolio. The positive ovarian cancer readout strengthens the strategic rationale for the transaction while leaving manufacturing scale, launch execution and market adoption as future tests.
How did Genmab shares respond to the positive Phase 3 survival announcement?
Genmab’s Nasdaq-listed American depositary shares closed at approximately $43.79 on October 23, 2026, advancing 9.5% from the previous session’s $40.00 closing price. Trading volume reached approximately 13 million shares, substantially above recent daily activity, while the intraday price reached $44.34. The advance coincided with the announcement of positive RAINFOL-02 survival results and reflects a marked improvement in market pricing during the session.
The stock also recorded substantial gains over the preceding week, rising from $37.00 on October 16 to $43.79 on October 23. This represents an advance of approximately 18.4% across the five trading sessions. The movement indicates strong positive price momentum, although it should not be attributed entirely to the Phase 3 results without accounting for broader investor expectations and other company developments.
The clinical announcement provides a plausible explanation for the scale of investor interest because the trial reported statistically significant benefits on two major efficacy endpoints. An overall survival result can be particularly consequential for investors assessing the likelihood that an oncology medicine will support a future regulatory application and generate commercial demand. However, investors still lack complete survival-duration and Phase 3 safety data.
The distinction between clinical risk reduction and commercial certainty remains important. A successful pivotal trial can improve expectations around a development asset, but it does not determine the eventual regulatory label, pricing or market share. Competition and treatment sequencing may also influence the realised financial value of Rina-S.
Genmab has scheduled an investor update for October 28, 2026, providing a near-term opportunity to clarify development priorities and the company’s interpretation of the results. Investors will be particularly interested in the regulatory engagement strategy, the timing of fuller clinical disclosures and the implications for commercial preparation.
What must happen before rinatabart sesutecan can move toward regulatory approval?
Genmab has said it intends to discuss the RAINFOL-02 results with regulatory authorities worldwide and submit the data for presentation at a future medical meeting. As of October 24, 2026, the company has not announced that a marketing application based on the results has been accepted for review. Rina-S therefore remains investigational, and the Phase 3 success does not constitute marketing authorisation.
Regulators will need to assess the complete efficacy and safety dataset, including details not contained in the initial announcement. These are likely to include median progression-free and overall survival, objective response rates, duration of response, subgroup outcomes and comparative adverse-event findings. The maturity of overall survival follow-up and the consistency of treatment effects across clinically relevant populations will also be important.
The study’s open-label design may place additional emphasis on the blinded independent central review assessment of progression-free survival. While the primary investigator-assessed endpoint was statistically significant, an independent assessment can provide useful corroboration of radiographic outcomes. Concordance between the two assessments would strengthen confidence in the progression-free survival interpretation.
Manufacturing and product-quality requirements will form another component of the regulatory pathway. Antibody-drug conjugates require consistent production of the antibody, linker and cytotoxic payload, together with control of drug-to-antibody characteristics and other quality attributes. Successful clinical results do not automatically establish that manufacturing systems and commercial supply arrangements satisfy every regulatory requirement.
Genmab will also need to determine the proposed treatment population and how prior exposure to approved therapies should be reflected in its regulatory strategy. The trial’s primary analysis population explicitly accounts for mirvetuximab treatment in certain high-expression patients, making prior therapy an important consideration. The final indication will depend on the submitted evidence and decisions by individual regulatory agencies.
If authorised, implementation will require oncology infusion services, appropriate adverse-event monitoring and reimbursement arrangements. The treatment’s three-week administration schedule may fit existing chemotherapy workflows, but actual uptake will depend on its approved use, clinical benefit-risk profile and availability within cancer treatment systems.
What will determine whether Rina-S becomes a meaningful new option for platinum-resistant ovarian cancer?
The RAINFOL-02 results establish that rinatabart sesutecan achieved statistically significant advantages over selected chemotherapy regimens in both progression-free and overall survival. The magnitude of the reported hazard ratios provides strong evidence of comparative activity in the randomised population studied. These findings move the programme beyond the uncertainty associated with response rates from earlier single-arm trials.
The next evidence package will need to establish the absolute magnitude of the survival benefits and how consistently they apply across folate receptor alpha expression groups, previous treatment histories and other clinically relevant characteristics. Detailed safety results will determine how the survival advantages should be balanced against toxicity and treatment burden. Those assessments will be especially important when comparing Rina-S with approved options that were not direct comparators in RAINFOL-02.
The positive Phase 3 readout also supports Genmab’s broader investment in antibody-drug conjugates and its decision to acquire ProfoundBio. However, the economic significance of the results remains dependent on regulatory progression and future commercial performance. Clinical success in platinum-resistant ovarian cancer cannot be assumed to guarantee successful development in other malignancies.
For Genmab, the immediate development priority is translating the topline survival findings into a complete evidence package suitable for regulatory discussion and scientific scrutiny. The full RAINFOL-02 dataset will determine whether Rina-S can progress from a promising late-stage medicine to an authorised treatment with a clearly defined role in an increasingly competitive ovarian cancer market.
